title: Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
abstract: Two children with active metastatic neuroblastoma after high dose chemotherapy and bone marrow transplantation (BMT) received a high dose continuous infusion of interleukin-2 (IL2) 120 days after an autologous BMT for patient 1 and 90 days after an allogeneic non T cell-depleted BMT for patient 2. Usual side effects of IL2 therapy were observed without life-threatening complications or any major hematological toxicity. The reactivation of graft-versus-host disease during IL2 infusion in patient 2 was the major BM-related complication but it improved with IL2 interruption and corticosteroids. IL2 induced a complete remission (9+ months) in patient 1 with the disappearance of bone metastases and local tumor but patient 2 progressed after cessation of therapy. Patient 1 presented with a large excess of circulating NK cells in the period after autologous BMT and IL2 induced a preferential outgrowth of this lymphocyte subset.
authors: Centre Léon Bérard, Bone Marrow Transplant Unit, Lyon, France.
authors: M C
authors: MC
authors: Favrot
authors: D
authors: D
authors: Floret
authors: S
authors: S
authors: Negrier
authors: P
authors: P
authors: Cochat
authors: E
authors: E
authors: Bouffet
authors: D C
authors: DC
authors: Zhou
authors: C R
authors: CR
authors: Franks
authors: T
authors: T
authors: Bijman
authors: M
authors: M
authors: Brunat-Mentigny
authors: I
authors: I
authors: Philip
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology; D002648:Child; D003131:Combined Modality Therapy; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D009447:Neuroblastoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D007376:Interleukin-2